Overview

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer

Status:
Not yet recruiting
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of combining Actinium- J591 with radiation therapy or with androgen deprivation therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
Convergent Therapeutics, Inc.
Treatments:
Androgens